Fifth UCL Queen Square Motor Neuron Disease Centre Hybrid Symposium
06 September 2024, 9:30 am–6:00 pm
New Technologies, AI and Big Data for ALS: From genetics to physiology to therapies
This event is free.
Event Information
Open to
- All
Availability
- Yes
Cost
- Free
Organiser
-
Debbie Hadley – Department of Neuromuscular Diseases, UCL Queen Square Institute of Neurology020 3108 2710
Location
-
Lecture Theatre378: Institute of Neurology, 33 Queen Square33 Queen SquareLondonWC1N 3BGUnited Kingdom
Programme
09:30 – 09:40Welcome and an Introduction to the UCL QS MND Centre:Andrea Malaspina, Clinical Academic Lead for MND, UCL Queen Square
Session 1: Genetic Technologies
09:40 – 10:00Jan Veldink, University Medical Center Utrecht / UMC Utrecht Brain Center, Netherlands -Project MinE: the rare variant architecture of ALS in 2024
10:00 – 10:20Eran Hornstein, Department of Molecular Neuroscience, Weizmann Institute of Science, Israel -miRNA in ALS
10:20 – 10:40Clotilde Lagier-Tourenne, Massachusetts General Hospital/Harvard Medical School -Combining genetic and pharmacological screens to identify new therapeutic targets in ALS
10:40 – 11:00 Coffee Break
11:00 – 11:20Oscar Wilkins, UCL Queen Square Institute of Neurology -New Technologies for Gene Therapies in ALS
11:20 – 11:40Andrew Bassett, Wellcome Sanger Institute -A CRISPR approach to studying neurodegenerative disease
Session 2: Proteins, Lipidomics and Metabolism
11:40 – 12:00Tammaryn Lashley, UCL Queen Square Institute of Neurology -New Pathologies in ALS and FTD
12:00 – 12:20Benjamin Ryskeldi-Falcon, MRC Laboratory of Molecular Biology, University of Cambridge -Atomic pathology of ALS and FTD by cryo-EM of amyloid filaments
12:20 – 12:40Adrian Isaacs, UCL Queen Square Institute of Neurology -Insights from lipidomic approaches in ALS
12:40 – 13:00Luc Dupuis, University of Strasbourg [Virtual] -FUS: a broad role in muscle and vulnerable neurons in neuromuscular diseases
13:00 – 14:00 Lunch Break
Session 3: Immune System
14:00 – 14:20Sian Henson, William Harvey Research Institute – Queen Mary University of London -Immune senescence and ALS
14:20 – 14:40Albert La Spada, University of California Irvine School of Medicine -Delineating Novel Pathways of Motor Neuron Demise in ALS
14:40 – 15:10KEYNOTE:Steven Finkbeiner, Center for Systems and Therapeutics & Taube/Koret Center for Neurodegenerative Disease, Gladstone Institutes, University of California, San Francisco -AI and ALS: from image analysis to “thinking” microscopy
15:10 – 15:40 Tea Break
Session 4: AI and Big Data
15:40 – 16:00Jon Rohrer, UCL Queen Square Institute of Neurology -Digital and remote biomarkers in ALS/FTD
16:00 – 16:20Orla Hardiman, Trinity Biomedical Sciences Institute, Trinity College Dublin -PRECISION ALS
16:20 – 16:40James Cole, University College London, Department of Computer Science -Machine learning for multivariate prognostic models in MND
16:40 – 16:50 10-minute comfort break
16:50 – 17:10Clive Svendsen, Cedars Sinai, Medical Center, California [Virtual] -Using Answer ALS and organ chip models to revel specific deficits in iPSC derived motor neurons
17:10 – 17:20Ben Cryar, Principal Analyst Opportunity Assessment Group, LifeArc -LifeArc’s Vision for Data & AI in ALS Research
17:20 – 17:40Bethan Kilpatrick, BenevolentAI -AI augmented target identification in ALS, taking a disease mechanism approach, exemplifiedby our most advanced drug discovery programme
17:40 – 17:50Closing Remarks–Linda Greensmith, Scientific Lead for NMD, UCL Queen Square andAmmar Al-Chalabi, Co-Director, UK MND Research Institute
Fifth UCL Queen Square Motor Neuron Disease Centre International Symposium has been approved by the Federation of the Royal Colleges of Physicians of the United Kingdom for 6 category 1 (external) CPD credit(s)
Other events in this series